Advertisements
popular news

Abivax: 'A therapy, such as ABX464, treats patients that are already infected to promote recovery'

This biotechnology company harnessing the immune system to develop novel treatments for viral diseases, cancer and inflammatory diseases. Interview
To fight COVID-19, more than eleven vaccines are currently being tested. As the vaccine race continues in the world, promising startups could make a difference. One of them, Abivax, announced that the first patient in the Phase 2/3 trial of his solution ABX464 against COVID-19 was treated at the Centre Hospitalier Universitaire de Nice, France, during last summer. As a matter of fact, this investigational drug could "promote recovery or, prevent the severe form of Covid-19 disease," says its founder. The floor was given to Philippe Pouletty, M.D. Founder & Chairman and Prof. Hartmut Ehrlich, M.D. CEO of Abivax to discuss this innovation within our BlastingTalks project, which consists of focusing on the challenges that companies face during the evolution of the digital world and during this unprecedented period of health crisis. Your company helps to treat people with inflammatory, viral diseases and cancer by mobilizing the body’s natural immune system. Could you explain in...
Advertisements